Kentucky Bioprocessing LLC (KBP) and Bayer Innovation GmbH, a subsidiary of German pharmaceutical giant Bayer AG, are collaborating to develop a facility at KBP’s Owensboro plant for the production service of biopharmaceuticals. Based on Bayer’s proprietary magnICON® technology, plant-made pharmaceutical proteins and other high-value products will be produced in tobacco plants on commercial scale. KBP is investing $2 to $3 million to expand the partnership with Bayer and will adapt its existing facility for the installation of an automated system to accommodate production.
Add Comment